We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed the most recent trading day at $18.45, moving +1.54% from the previous trading session. This change outpaced the S&P 500's 0.02% loss on the day. Meanwhile, the Dow lost 0.03%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Coming into today, shares of the company had lost 4.47% in the past month. In that same time, the Medical sector lost 3.97%, while the S&P 500 lost 1.4%.
TEVA will be looking to display strength as it nears its next earnings release, which is expected to be February 14, 2019. In that report, analysts expect TEVA to post earnings of $0.56 per share. This would mark a year-over-year decline of 39.78%. Our most recent consensus estimate is calling for quarterly revenue of $4.53 billion, down 17.01% from the year-ago period.
Any recent changes to analyst estimates for TEVA should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TEVA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, TEVA is currently trading at a Forward P/E ratio of 6.48. This represents a discount compared to its industry's average Forward P/E of 12.15.
Also, we should mention that TEVA has a PEG ratio of 5.52. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA's industry had an average PEG ratio of 1.03 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 43, which puts it in the top 17% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) closed the most recent trading day at $18.45, moving +1.54% from the previous trading session. This change outpaced the S&P 500's 0.02% loss on the day. Meanwhile, the Dow lost 0.03%, and the Nasdaq, a tech-heavy index, lost 0.21%.
Coming into today, shares of the company had lost 4.47% in the past month. In that same time, the Medical sector lost 3.97%, while the S&P 500 lost 1.4%.
TEVA will be looking to display strength as it nears its next earnings release, which is expected to be February 14, 2019. In that report, analysts expect TEVA to post earnings of $0.56 per share. This would mark a year-over-year decline of 39.78%. Our most recent consensus estimate is calling for quarterly revenue of $4.53 billion, down 17.01% from the year-ago period.
Any recent changes to analyst estimates for TEVA should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. TEVA is currently sporting a Zacks Rank of #3 (Hold).
In terms of valuation, TEVA is currently trading at a Forward P/E ratio of 6.48. This represents a discount compared to its industry's average Forward P/E of 12.15.
Also, we should mention that TEVA has a PEG ratio of 5.52. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. TEVA's industry had an average PEG ratio of 1.03 as of yesterday's close.
The Medical - Generic Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 43, which puts it in the top 17% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.